keyword
https://read.qxmd.com/read/38630291/comparative-performance-of-scfv-based-anti-bcma-car-formats-for-improved-t-cell-therapy-in-multiple-myeloma
#21
JOURNAL ARTICLE
Sophia Stock, Luisa Fertig, Adrian Gottschlich, Janina Dörr, Florian Märkl, Lina Majed, Vivien D Menkhoff, Ruth Grünmeier, Kai Rejeski, David M Cordas Dos Santos, Sebastian Theurich, Michael von Bergwelt-Baildon, Stefan Endres, Marion Subklewe, Sebastian Kobold
In multiple myeloma (MM), B cell maturation antigen (BCMA)-directed CAR T cells have emerged as a novel therapy with potential for long-term disease control. Anti-BCMA CAR T cells with a CD8-based transmembrane (TM) and CD137 (41BB) as intracellular costimulatory domain are in routine clinical use. As the CAR construct architecture can differentially impact performance and efficacy, the optimal construction of a BCMA-targeting CAR remains to be elucidated. Here, we hypothesized that varying the constituents of the CAR structure known to impact performance could shed light on how to improve established anti-BCMA CAR constructs...
April 17, 2024: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/38630258/associations-of-granulocyte-colony-stimulating-factor-with-toxicities-and-efficacy-of-chimeric-antigen-receptor-t-cell-therapy-in-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia
#22
JOURNAL ARTICLE
Sha Ma, Ying Wang, Kunming Qi, Wenyi Lu, Yuekun Qi, Jiang Cao, Mingshan Niu, Depeng Li, Wei Sang, Zhiling Yan, Feng Zhu, Hai Cheng, Zhenyu Li, Mingfeng Zhao, Kailin Xu
Few studies have reported the associations of granulocyte colony-stimulating factor (G-CSF) with cytokine release syndrome (CRS), neurotoxic events (NEs) and efficacy after chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We present a retrospective study of 67 patients with R/R B-ALL who received anti-CD19 CAR T-cell therapy, 41 (61.2%) patients received G-CSF (G-CSF group), while 26 (38.8%) did not (non-G-CSF group). Patients had similar duration of grade 3-4 neutropenia between the two groups...
April 17, 2024: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/38629915/protocol-for-a-randomized-controlled-trial-to-evaluate-a-permissive-blood-pressure-target-versus-usual-care-in-critically-ill-children-with-hypotension-pressure
#23
JOURNAL ARTICLE
Robert Darnell, Alanna Brown, Emma Laing, Julia Edwards, David A Harrison, Joseph C Manning, Mark J Peters, Padmanabhan Ramnarayan, Samiran Ray, Zia Sadique, Barnaby R Scholefield, Dermot Shortt, Lamprini Lampro, Carly Au, Kathy M Rowan, Paul Mouncey, David P Inwald
OBJECTIVES: Management of hypotension is a fundamental part of pediatric critical care, with cardiovascular support in the form of fluids or vasoactive drugs offered to every hypotensive child. However, optimal blood pressure (BP) targets are unknown. The PRotocolised Evaluation of PermiSSive BP Targets Versus Usual CaRE (PRESSURE) trial aims to evaluate the clinical and cost-effectiveness of a permissive mean arterial pressure (MAP) target of greater than a fifth centile for age compared with usual care...
April 17, 2024: Pediatric Critical Care Medicine
https://read.qxmd.com/read/38629814/early-evaluation-of-car-t-cell-therapy-response-in-r-r-dlbcl-patients-using-18-f-fdg-pet-ct
#24
JOURNAL ARTICLE
Kazuhiro Kitajima, Hiroyuki Yokoyama, Reona Wada, Yukihisa Tamaki, Kyoko Yoshihara, Katsuji Kaida, Satoshi Yoshihara, Koichiro Yamakado
OBJECTIVE: CD19-targeted chimeric antigen receptor T (CAR-T) cell therapy provides a durable response in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). The role of fluorine-18-fluorodeoxyglucose (18 F-FDG) positron emission tomography/computed tomography (PET/CT) for early evaluation of responsein patients with that immunotherapy was evaluated. SUBJECTS AND METHODS: Three separate 18 F-FDG PET/CT examinations of 53 patients (29 males, 24 females; median 62 years old) with R/R DLBCL were conducted; before bridging therapy [time of decision (TD)], before CAR-T (tisagenlecleucel, n=37; lisocabtagenemaraleucel, n=16) infusion [time of CAR-T infusion (IT)], and one month (M1) after CAR-T infusion...
April 18, 2024: Hellenic Journal of Nuclear Medicine
https://read.qxmd.com/read/38628287/exploring-the-efficacy-and-safety-of-anti-bcma-chimeric-antigen-receptor-t-cell-therapy-for-multiple-myeloma-systematic-review-and-meta-analysis
#25
JOURNAL ARTICLE
Jia Zhang, Xinhua Ding, Xiaoxiao Ding
OBJECTIVE: Multiple myeloma (MM) is a bone marrow cancer that profoundly affects plasma cells involved in the immune response. Myeloma cells alter the average production of cells in the bone marrow. Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy allows genetic modifications of an individual's T-cells to increase the expression of CARs used to identify and attach BCMA proteins to the malignant cells. Our main objective is to perform a systematic review and meta-analysis to explore the efficacy and safety of anti-BCMA CAR T-cell therapy for MM...
2024: CytoJournal
https://read.qxmd.com/read/38627969/evolution-of-the-clinical-stage-hyperactive-tcbuster-transposase-as-a-platform-for-robust-non-viral-production-of-adoptive-cellular-therapies
#26
JOURNAL ARTICLE
Joseph G Skeate, Emily J Pomeroy, Nicholas J Slipek, Bryan J Jones, Bryce J Wick, Jae-Woong Chang, Walker S Lahr, Erin M Stelljes, Xiaobai Patrinostro, Blake Barnes, Trevor Zarecki, Joshua B Krueger, Jacob E Bridge, Gabrielle M Robbins, Madeline D McCormick, John R Leerar, Kari T Wenzel, Kathlyn M Hornberger, Kirsti Walker, Dalton Smedley, David A Largaespada, Neil Otto, Beau R Webber, Branden S Moriarity
Cellular therapies for the treatment of human diseases, such as chimeric antigen receptor (CAR) T and NK cells have shown remarkable clinical efficacy in treating hematological malignancies, however current methods mainly utilize viral vectors which are limited by their cargo size capacities, high cost, and long timelines for production of clinical reagent. Delivery of genetic cargo via DNA transposon engineering is a more timely and cost-effective approach, yet has been held back by less efficient integration rates...
April 15, 2024: Molecular Therapy
https://read.qxmd.com/read/38627667/development-and-validation-of-the-cannabis-exposure-in-pregnancy-tool-cept-a-mixed-methods-study
#27
JOURNAL ARTICLE
Kathleen H Chaput, Carly A McMorris, Amy Metcalfe, Catherine Ringham, Deborah McNeil, Shaelen Konschuh, Laura J Sycuro, Sheila W McDonald
BACKGROUND: Evidence of associations between prenatal cannabis use (PCU) and maternal and infant health outcomes remains conflicting amid broad legalization of cannabis across Canada and 40 American states. A critical limitation of existing evidence lies in the non-standardized and crude measurement of prenatal cannabis use (PCU), resulting in high risk of misclassification bias. We developed a standardized tool to comprehensively measure prenatal cannabis use in pregnant populations for research purposes...
April 16, 2024: BMC Pregnancy and Childbirth
https://read.qxmd.com/read/38627450/development-and-validation-of-an-automated-computational-approach-to-grade-immune-effector-cell-associated-hematotoxicity
#28
JOURNAL ARTICLE
Emily C Liang, Kai Rejeski, Teng Fei, Aya Albittar, Jennifer J Huang, Andrew J Portuguese, Qian Wu, Sandeep Raj, Marion Subklewe, Roni Shouval, Jordan Gauthier
Hematologic toxicity frequently complicates chimeric antigen receptor (CAR) T-cell therapy, resulting in significant morbidity and mortality. In an effort to standardize reporting, the European Hematology Association (EHA) and European Society of Blood and Marrow Transplantation (EBMT) devised the immune effector cell-associated hematotoxicity (ICAHT) grading system, distinguishing between early (day 0-30) and late (after day +30) events based on neutropenia depth and duration. However, manual implementation of ICAHT grading criteria is time-consuming and susceptible to subjectivity and error...
April 16, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38627181/practical-aspects-of-immunotherapy-a-report-from-the-20th-international-myeloma-society-ims-annual-meeting
#29
JOURNAL ARTICLE
Noopur S Raje, Adam D Cohen, Krina K Patel, Niels W C J van de Donk, Joshua Richter, Jesus San-Miguel
Immunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies. Here, we highlight the discussion during this session, including the role of CAR-T and bsAb therapies in frontline MM treatment, management of acute toxicities, prevention and management of infections, and finally treatment sequencing of T-cell redirected therapies...
March 22, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38627021/preconception-counselling-in-women-of-reproductive-age-attending-cardiology-clinics-in-scotland
#30
JOURNAL ARTICLE
Joanna Osmanska, Alice M Jackson, Joanne Simpson, Carly Adamson, Daniel Doherty, Helene Mamet, Lynsey Moir, Niki L Walker, Duncan Hogg, Maggie Simpson
BACKGROUND: Guidelines for the management of cardiovascular disease (CVD) recommend preconception risk stratification and counselling in all women of childbearing age. We assessed the provision of preconception counselling (PCC) among women of reproductive age attending general cardiology outpatient clinics over a 12-month period in two large health boards in Scotland. METHODS AND RESULTS: Electronic health records were reviewed and data on patient demographics, cardiac diagnoses, medication use and the content of documented discussions regarding PCC were recorded...
April 16, 2024: Heart
https://read.qxmd.com/read/38626595/factors-associated-with-adherence-to-the-principles-of-responsible-companion-animal-guardianship-in-a-municipality-in-southeastern-brazil
#31
JOURNAL ARTICLE
Klauber Menezes Penaforte, Eduardo Sérgio da Silva, Saulo Nascimento de Melo, Paulo Henrique Araújo Soares, Cláudia Maria de Souza Gonçalves, Renata Aparecida Nascimento Ribeiro, Marco Aurélio Pereira Horta, Sarah de Faria Lélis, Clara Guimarães Silveira, Fabiano Borges Figueiredo, Rafael Gonçalves Teixeira-Neto, Vinícius Silva Belo
Responsible companion animal guardianship (RCAG) covers aspects that are relevant to both animal and human health. Understanding the factors associated with adherence to RCAG principles can guide accountability, animal welfare and disease control. The present observational study describes the level of adherence to RCAG by guardians living in a medium-sized Brazilian municipality and identifies the factors associated with inadequate guardianship. Questionnaires were administered to randomly selected guardians of 704 dogs...
April 10, 2024: Preventive Veterinary Medicine
https://read.qxmd.com/read/38626338/enhancing-glioblastoma-immunotherapy-with-integrated-chimeric-antigen-receptor-t-cells-through-the-re-education-of-tumor-associated-microglia-and-macrophages
#32
JOURNAL ARTICLE
Nianci Zhu, Sijia Chen, Yu Jin, Meng Wang, Luyao Fang, Lingjing Xue, Dexiang Hua, Ziyao Zhang, Meng Jia, Meixi Hao, Can Zhang
Glioblastoma (GBM) is an aggressive brain cancer that is highly resistant to treatment including chimeric antigen receptor (CAR)-T cells. Tumor-associated microglia and macrophages (TAMs) are major contributors to the immunosuppressive GBM microenvironment, which promotes tumor progression and treatment resistance. Hence, the modulation of TAMs is a promising strategy for improving the immunotherapeutic efficacy of CAR-T cells against GBM. Molecularly targeting drug pexidartinib (PLX) has been reported to re-educate TAMs toward the antitumorigenic M1-like phenotype...
April 16, 2024: ACS Nano
https://read.qxmd.com/read/38626305/how-to-manage-prolonged-immune-effector-cell-associated-hematotoxicity-icaht-related-to-bcma-directed-myeloma-therapy
#33
EDITORIAL
James A Davis, Mary McGann, Jessica Marini, Hamza Hashmi
No abstract text is available yet for this article.
April 16, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38626223/online-therapy-with-families-what-can-families-tell-us-about-how-to-do-this-well-a-qualitative-study-assessing-families-experience-of-remote-dyadic-developmental-psychotherapy-compared-to-face-to-face-therapy
#34
JOURNAL ARTICLE
Monica Blair, Leigh Tweedlie, Helen Minnis, Irene Cronin, Fiona Turner
Dyadic Developmental Psychotherapy (DDP) is a family-based therapy for adopted children aiming to achieve secure attachment between the child and parent. Due to restrictions under the COVID-19 pandemic, delivery of DDP transitioned from face-to-face to online methods. This study aimed to explore families experience of online DDP compared to face-to-face DDP, looking at the advantages and disadvantages of remote delivery methods and the implications this has on future service delivery for clinicians. Semi-structured interviews with 6 families were conducted online...
2024: PloS One
https://read.qxmd.com/read/38625911/travel-burdens-to-access-care-among-children-with-cancer-between-2016-and-2019-analysis-of-a-national-population-based-cancer-registry-in-japan
#35
JOURNAL ARTICLE
Anna Tsutsui, Yoshitaka Murakami, Satomi Okamura, Takako Fujimaki, Masayuki Endo, Yuko Ohno
BACKGROUND: Centralization of cancer care increases survival but increases the travel burden (i.e., travel durations, distances, and expenditures) in visiting hospitals. This study investigated the travel burdens to access cancer care for children aged 18 years and younger in Japan. METHODS: The study population comprised 10,709 patients diagnosed between 2016 and 2019 obtained from a national population-based cancer registry in Japan. Their residences were classified as urban or rural...
2024: PloS One
https://read.qxmd.com/read/38625072/complex-association-of-body-mass-index-and-outcomes-in-patients-with-relapsed-and-refractory-multiple-myeloma-treated-with-car-t-cell-immunotherapy
#36
JOURNAL ARTICLE
Hai Cheng, Yingjun Sun, Xiaoxue Zhang, Zihan Chen, Lingyan Shao, Jiaying Liu, Dandan Wang, Yegan Chen, Xue Wang, Wei Chen, Wei Sang, Kunming Qi, Zhenyu Li, Cai Sun, Ming Shi, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Junnian Zheng, Kailin Xu, Jiang Cao
BACKGROUND AIMS: Chimeric antigen receptor-T (CAR-T) cells have exhibited remarkable efficacy in treating refractory or relapsed multiple myeloma (R/R MM). Although obesity has a favorable value in enhancing the response to immunotherapy, less is known about its predictive value regarding the efficacy and prognosis of CAR-T cell immunotherapy. METHODS: We conducted a retrospective study of 111 patients with R/R MM who underwent CAR-T cell treatment. Using the body mass index (BMI) classification, the patients were divided into a normal-weight group (73/111) and an overweight group (38/111)...
March 29, 2024: Cytotherapy
https://read.qxmd.com/read/38625071/car-t-cell-expansion-platforms-yield-distinct-t-cell-differentiation-states
#37
JOURNAL ARTICLE
Hannah W Song, Michaela Prochazkova, Lipei Shao, Roshini Traynor, Sarah Underwood, Mary Black, Vicki Fellowes, Rongye Shi, Marie Pouzolles, Hsien-Chao Chou, Adam T Cheuk, Naomi Taylor, Ping Jin, Robert P Somerville, David F Stroncek, Javed Khan, Steven L Highfill
With investigators looking to expand engineered T cell therapies such as CAR-T to new tumor targets and patient populations, a variety of cell manufacturing platforms have been developed to scale manufacturing capacity using closed and/or automated systems. Such platforms are particularly useful for solid tumor targets, which typically require higher CAR-T cell doses. Although T cell phenotype and function are key attributes that often correlate with therapeutic efficacy, how manufacturing platforms influence the final CAR-T cell product is currently unknown...
March 12, 2024: Cytotherapy
https://read.qxmd.com/read/38624121/experimental-study-of-rotational-relaxation-for-d2-1-12-in-collisions-with-n2
#38
JOURNAL ARTICLE
Lin Mao, Jing Liu, Nurali Habibulla, Yongbao Qiu
The rotational relaxation behavior of D2(1,12) in a D2-N2 mixture was investigated using coherent anti-Stokes Raman scattering (CARS) technique. The rovibrational level v = 1 and J = 12 of D2 was selectively excited through stimulated Raman pumping while monitoring the temporal evolution of population for D2(1, J ≤ 12) molecules using time-resolved CARS spectroscopy. The results demonstrate that the rotational relaxation processes of D2(1,12) encompass both multi-quantum relaxation and continuous single-quantum relaxation...
April 21, 2024: Journal of Chemical Physics
https://read.qxmd.com/read/38623656/evaluation-of-laboratory-parameters-as-predictors-of-mortality
#39
JOURNAL ARTICLE
Yasin Altun, Halime D Balci
BACKGROUND: Evaluation of biomarkers as risk factors for mortality may provide early intervention and treatment for fatal diseases. We aimed to determine the usability of inexpensive and easily measurable tests in the differentiation of critically ill patients by investigating their relationship with mortality. METHODS: This study was executed by examining the sixth, third, and first month examinations of patients registered to the home health care services unit in 2022 before mortality due to any reason...
April 1, 2024: Clinical Laboratory
https://read.qxmd.com/read/38623491/clinical-utility-of-c-reactive-protein-to-albumin-ratio-in-the-management-of-patients-with-inflammatory-bowel-disease
#40
JOURNAL ARTICLE
Anke L Nguyen, Claudia Brick, David Liu, David J Gibson, Peter R Gibson, Miles P Sparrow
BACKGROUND AND AIM: C-reactive protein (CRP)-to-albumin ratio (CAR) is a novel score with prognostic value in inflammatory conditions. This study assessed the performance of CAR as an objective marker of disease activity and prediction of subtherapeutic infliximab trough levels in patients with inflammatory bowel disease (IBD). METHODS: A retrospective study was conducted on three different patient cohorts with IBD: patients who had (i) fecal calprotectin (FC) measurements; (ii) Mayo Endoscopic Scores; and (iii) infliximab trough levels available...
April 2024: JGH Open: An Open Access Journal of Gastroenterology and Hepatology
keyword
keyword
10800
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.